Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

HIV vaccine in worldwide trial

08.10.2003


Vanderbilt is one of nine US sites



Vanderbilt University Medical Center is participating in worldwide tests of a potential vaccine that can stimulate important immune responses against the virus that causes AIDS.

This is the first candidate vaccine against the human immunodeficiency virus (HIV) to be studied simultaneously in so many locations, from Brazil to Thailand, according to Merck & Co. Inc., which developed the vaccine.


Vanderbilt currently is testing six potential AIDS vaccines, but the Merck product has gone farther than any other in generating cellular immune responses in preliminary human tests, says Dr. Paul Spearman, co-principal investigator of the Vanderbilt HIV Vaccine Program, one of nine U.S. sites to participate in the study.

Cellular immune responses refer to the production of a type of white blood cell, known as a cytotoxic or "killer" T-cell, which can clear its virus-infected neighbors from the bloodstream. Scientists believe that by speeding up production of these cells, a vaccine may be able to prevent the virus from spreading in the body.

"It may not prevent infection, but it might stimulate a response that would prevent the disease that results from the infection," Spearman says.

The Vanderbilt program is part of the federally funded HIV Vaccine Trials Network, an international coalition of scientists and institutions dedicated to accelerating the search for an HIV vaccine. This is the first collaboration between Merck and the network. The phase I trial is designed to test – at varying doses -- the vaccine’s safety and ability to stimulate immune responses in healthy, uninfected volunteers between the ages of 18 and 50. Of the 435 volunteers who will participate in the study worldwide, about a dozen will be tested at Vanderbilt.

Volunteers will be randomly selected to receive three injections of the either the vaccine or an inactive "placebo." The study involves 24 clinic visits and 22 blood tests over the course of 18 months.

A goal of the study is to see whether a single vaccine can generate significant immune responses in diverse populations throughout the world. If the trial is successful, more extensive testing will be conducted, ultimately leading to studies in people at risk of being infected with HIV.

The research is moving "fairly quickly," Spearman says. "We’re really hopeful."

The vaccine consists of a synthetically produced HIV gene – which cannot cause HIV infection. The gene is carried by an adenovirus, which normally can cause symptoms of the common cold, but which has been genetically altered so that is harmless. Side effects of the vaccine in preliminary human studies have been mild. They include soreness at the injection site and, at higher doses than will be used in this study, flu-like symptoms in some people.

Clinton Colmenares | EurekAlert!
Further information:
http://www.hivvaccineresearch.com
http://www.mc.vanderbilt.edu/reporter/

More articles from Health and Medicine:

nachricht Potential seen for tailoring treatment for acute myeloid leukemia
10.12.2018 | University of Washington Health Sciences/UW Medicine

nachricht UC San Diego researchers develop sensors to detect and measure cancer's ability to spread
06.12.2018 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

Im Focus: Substitute for rare earth metal oxides

New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals

Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.

Im Focus: A bit of a stretch... material that thickens as it's pulled

Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.

Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...

Im Focus: The force of the vacuum

Scientists from the Theory Department of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science (CFEL) in Hamburg have shown through theoretical calculations and computer simulations that the force between electrons and lattice distortions in an atomically thin two-dimensional superconductor can be controlled with virtual photons. This could aid the development of new superconductors for energy-saving devices and many other technical applications.

The vacuum is not empty. It may sound like magic to laypeople but it has occupied physicists since the birth of quantum mechanics.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

Expert Panel on the Future of HPC in Engineering

03.12.2018 | Event News

 
Latest News

Small but ver­sat­ile; key play­ers in the mar­ine ni­tro­gen cycle can util­ize cy­anate and urea

10.12.2018 | Life Sciences

New method gives microscope a boost in resolution

10.12.2018 | Physics and Astronomy

Carnegie Mellon researchers probe hydrogen bonds using new technique

10.12.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>